CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology

CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology

We developed a SARS-CoV-2 vaccine candidate (CoV-RBD121-NP) comprised of a tobacco mosaic virus-like nanoparticle conjugated to the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 fused to a human IgG1 Fc domain. CoV-RBD121-NP elicits strong antibody responses in C57BL/6 mice and is...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jennifer K. DeMarco, Joshua M. Royal, William E. Severson, Jon D. Gabbard, Steve Hume, Josh Morton, Kelsi Swope, Carrie A. Simpson, John W. Shepherd, Barry Bratcher, Kenneth E. Palmer, Gregory P. Pogue
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
SARS-CoV-2
COVID-19
betacoronavirus
vaccine
betacoronaviridae
TMV
Medicine
R
Accès en ligne:https://doaj.org/article/d948abd924354895b2c5b1c46d082bd9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Documents similaires